tested them for proteolytic activity in a trans-cleavage assay. The region from amino acids 1541-1855 was the smallest fragment with proteolytic activity. 3 To identify the important features of this segment, we aligned the amino acid sequences of 15 papain-like protease domains from 8 different coronaviruses with that of SARS-CoV PLpro1541-1855. While there is only an 18-32% identity between the sequences, there are some important conserved features, including the catalytic cysteine and histidine residues (identified as C1651 and H1812 for SARS-CoV PLpro) 2 and a conserved Zn-binding finger, which has been shown to be important for proteolytic activity of HCoV-229E PLP1. 4 In addition, we identified an aspartic acid residue (D1826 in SARS-CoV PLpro), which is conserved amongst all the coronavirus papain-like proteases. We found that PLpro in which D1826 was replaced by an alanine had no detectable proteolytic activity in the cellular trans-cleavage assay, 3 indicating that this residue may play an important role in proteolytic activity. We predict that this residue forms a part of a catalytic triad with the catalytic cysteine and histidine residues, similar to the active sites of other papain-like proteases. 5 Ultimately, crystallographic data will be critical for a complete understanding of the coronavirus PLpro active site.
DEUBIQUITINATING ACTIVITY OF SARS-CoV PLpro.
Interestingly, an independent bioinformatics study predicted that SARS-CoV PLpro may have structural similarity to a cellular deubiquitinating enzyme, HAUSP (herpesvirus-associated ubiquitin-specific protease). 6, 7 On the basis of this similarity in molecular architecture and the predicted specificity of PLpro for cleavage after a diglycine residue, Sulea and co-workers predicted that PLpro has deubiquitinating (DUB) activity.
To test this prediction we used our experimentally determined catalytic core domain in an in vitro assay for deubiquitination. 7 Briefly, wild-type PLpro and mutated versions where C1651 or D1826 was replaced by alanine, were expressed in E. coli BL21 and purified to homogeneity. 3 In the assay, purified WT PLpro was incubated alone (Fig. 1 , lane 2) or with di-ubiquitin substrate (Boston Biochem) (lane 3) for 1 hour at 37°C in a buffer containing BSA. In lanes 4 and 5, purified mutant PLpro D1826A and PLpro C1651A respectively were incubated with the substrate. WT PLpro cleaved the substrate completely, while the C1651A mutant had no activity. As expected, the D1826A mutant showed a small amount of processing activity. This is the first evidence that SARS-CoV PLpro is able to cleave a ubiquitinated substrate.
To study the kinetics of proteolysis and deubiquitination by PLpro, we established a FRET-based assay using a substrate [E-EDANS]RELNGGAPI-[KDABCYL]S for proteolysis. This substrate is based on the naturally occurring nsp1/nsp2 and nsp2/nsp3 cleavage sites for PLpro. A similar assay using the commercially available substrate, ubiquitin-AMC (Boston Biochem) was used to measure the kinetics of deubiquitination. The substrates were incubated with the purified proteins and the reaction was allowed to go to completion. The fluorescence released was measured on a Cary Eclipse fluorescence spectrophotometer. 
Since the enzyme could not be saturated with substrate, pseudo-first rate order kinetics were used to calculate the apparent k cat / k m (k app ), indicated in Table 1 . WT PLpro1541-1855 cleaved the ubiquitin substrate with faster kinetics than the peptide substrate, though this might reflect in vitro conditions and the substrates used. However in a similar assay, HAUSP cleaved ubiquitin-AMC with a k cat /K m of 13 min 1 mM 1 (Hu deubiquitinase. The mutant D1826A hydrolyzed peptide substrate at approximately 1% of the efficiency of the WT, which is consistent with an assisting role for this residue in a catalytic triad with the catalytic cysteine and histidine residues. The C1651A mutant showed no cleavage activity with either substrate, demonstrating the essential role of the catalytic cysteine residue (Johnston et al., 1997).
A "SIGNATURE SEQUENCE" FOR DEUBIQUITINATION ACTIVITY
Sulea and co-workers noted "structural signatures for strict specificity" (Sulea et al., 2005) present in HAUSP and also in some of the coronavirus papain-like proteases, which form part of the substrate-binding site. In the case of SARS-CoV PLpro the residues Y1804 and Y1813 occlude the substrate-binding site, imposing the requirement for the small diglycine residues at the cleavage site (Sulea et al., 2005) . Our alignment of the amino acid sequences of 16 papain-like proteases from nine coronaviruses shows that the "signature sequence" is present in twelve of these sequences. This suggests that these proteases may also have deubiquitinating activity, though this remains to be experimentally verified. 
SCoV PLp1804 YT---GNYQCGH-Y-T-HITAKETLYR----<32>IKP-------------%ID MHVJ P2 1867 FT---GG-SVGH-Y-T-HVKCKPKYQL----<35?>YY--------------32
BCoV P2 1822 FK---GD-KVGH-Y-V-HVKCEQSYQL----<35>YY--------------31 0C43 P2 1822 FI---GD-KVGH-Y-V-HVKCEQSYQL----<35>YY--------------30 HKU P2 1907 FM---G-VGVGH-Y-T-HLKCGSPYQH----<32>LTNY------------28 229E P2 1857 FS---GPVDKGH-Y-TVYDTAKKSMY-----<30>VK--------------22 TGEV P2 1736 YS---GSNRNGH-Y-T-YYDNRNGLV-----<25>KKPQAEERPKNCAFNK 22 IBV PLp1490 FV---GSTNSGHCY-T-QAAGQ----A----<30>SLPV------------22 NL63 P2 1825 YTTFSGSFDNGH-Y-VVYDAANNAVY-----<28>VPTIVSEK--------21 TGEV P1 1237 YT---GTTQNGH-Y-M--VDDIEHGYC----<28>EKPKQEFKVEKVEQQ-21 229E P1 1197 FR---GAVSCGH-YQT-NIYSQNLC------<37>IKNTVD----------20 NL63 P1 1204 YL---GVKGSGH-Y-------QTNLYSFNKA<33>VKPFAVYKNVK-----19 HKU P1 1306 VD---VNVC--H-S-V-AVIGDE---Q----<36>ITPNVCF---------20 MHVJ P1 1267 VN------DCHS-M-A-VVDGKQ--------<38>ITPNVCF---------18 OC43 P1 1199 KR---IVYKAAC-V-V-DVNDSHSMAV----<43>ITPNVCF---------18 BCoV P1 1199 KR---SVYKAAC-V-V-DVNDSHSMAV----<43>ITPNVCF---------18
FUTURE DIRECTIONS
Here, we have identified a core catalytic domain for SARS-CoV PLpro that is capable of processing both the amino-terminal end of the replicase polyprotein and ubiquitinated substrates. The role of this deubiquitinating activity in SARS-CoV-infected cells is unknown. Future experiments will focus on determining if this SARS-CoV PLpro DUB is active in virus-infected cells, investigating the significance of DUB activity in the viral life cycle, as well as identifying possible viral and cellular targets.
